Main Sector
Biotechnology - Therapeutics and Diagnostics
Subsectors
Drug delivery
Peptides
Small molecules
Indication
Endocrine, nutritional and metabolic diseases / endocrinology
Products
In development: 6
Description
Kailera Therapeutics is a clinical-stage biopharmaceutical company focused on developing next-generation therapies for obesity and related metabolic conditions. The company aims to offer a "diversified portfolio" of treatments, including both injectable and oral formulations, to address various patient needs in chronic weight management. The company's products include Ribupatide (KAI-9531), Oral Ribupatide, KAI-7535, KAI-4729, etc.
